7.5 Compounding Workflow: SOPs, Workflow Software, Production Queues & Labeling

BCSCP Board Certified Sterile Compounding Pharmacist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview, USP Standards & CSP Categories

1.1 BCSCP Exam Format, Eligibility, Scoring & 2024 Content Outline 1.2 USP <797> Scope, Core Philosophy & Regulatory Framework 1.3 USP <797> Categories 1, 2, and 3 CSP Classification 1.4 Immediate-Use CSPs: The 4-Hour Rule and Its Conditions

2 Chapter 2: Facilities, Engineering Controls & Cleaning

2.1 Cleanroom Architecture & ISO Classifications 2.2 Primary Engineering Controls (PECs) & Laminar Airflow Dynamics 2.3 Segregated Compounding Areas (SCAs) & Containment SCAs (C-SCAs) 2.4 HVAC Engineering Controls, Pressure Differentials & Air Exchange 2.5 Equipment & Materials in Classified Areas Under Dynamic Conditions 2.6 Cleaning, Disinfecting, Sporicidal Agents & Sterile 70% IPA 2.7 Contingency Planning: Power, HVAC, Supply and Staffing Failures

3 Chapter 3: Environmental Monitoring & Facility Certification

3.1 Viable Airborne Microbial Monitoring 3.2 Total Airborne Non-Viable Particle Counting & Cleanroom Certification Standards 3.3 Surface Microbial Sampling: Contact Plates, Swabs, Incubation Protocols & Action Levels 3.4 Environmental Sampling Excursions, Trend Analysis, and Remediation Protocols

4 Chapter 4: Hand Hygiene, Garbing & Aseptic Technique

4.1 Hand Hygiene & Cleansing Protocols 4.2 Step-by-Step Garbing Sequence & Ante-Room Logistics 4.3 Direct Compounding Area (DCA) Aseptic Technique & First Air Integrity

5 Chapter 5: Beyond-Use Dating, Storage & Container Rules

5.1 Category 1 Beyond-Use Dating & Storage Limitations 5.2 Category 2 Beyond-Use Dating: Sterile vs. Nonsterile Starting Components 5.3 Category 3 Beyond-Use Dating: Requirements for Extended Dating (60/90/120 Days) 5.4 Container Types, Puncture Limits & Multi-Dose Container Rules

6 Chapter 6: Sterilization, Release Testing & Hazardous Drug Compounding

6.1 Terminal Sterilization vs. Sterilizing Filtration 6.2 Release Testing: Sterility (USP <71>), Endotoxin (USP <85>) & Particulates (USP <788>) 6.3 Container Closure Integrity Testing (CCIT) & Visual Inspection 6.4 USP <800> Hazardous Drug Compounding & Closed System Drug-Transfer Devices (CSTDs)

7 Chapter 7: Materials, Equipment & Compounding Workflow

7.1 Compounding Equipment & Technology: ACDs, Balances, Pumps & IV Workflow Systems 7.2 Compounding Supplies, Containers & Closures 7.3 Component Receipt, Storage & Material Transfer 7.4 Calibration, Verification, Validation & Maintenance of Equipment 7.5 Compounding Workflow: SOPs, Workflow Software, Production Queues & Labeling 7.6 Handling, Storing, Packaging, Transporting & Disposing of Finished CSPs

8 Chapter 8: Calculations, Osmolarity & Physicochemical Compatibility

8.1 Sterile Compounding Calculations: Millimoles, Milliequivalents, Osmolarity & Tonicity Adjustments 8.2 Physical and Chemical Incompatibilities: pH Effects, Salt Formations & Precipitation Mechanisms 8.3 Complex Admixture Compatibility: Calcium-Phosphate Solubility Curves & Parenteral Nutrition Dynamics

9 Chapter 9: Therapeutics, Administration & Patient Monitoring

9.1 Patient-Specific Parameters: Verifying CSP Orders 9.2 Special Administration Routes: Epidural, Intrathecal, Ophthalmic & Intravesical Sterile Preparations 9.3 Medication Delivery Devices, Home Infusion & Patient Education 9.4 High-Alert Sterile Medications, Pediatric/Neonatal Considerations & Extravasation Management 9.5 Therapeutic Drug Monitoring, Catheter-Related Bloodstream Infection (CRBSI) Prevention & Clinical Vigilance 9.6 Medication Adherence in Home and Outpatient Sterile Therapy 9.7 Interprofessional Care Coordination for Sterile Preparations

10 Chapter 10: Quality Management, Records & Personnel Competency

10.1 Master Formulation Records (MFR) vs. Compounding Records (CR) Requirements & Workflow 10.2 Personnel Training, Core Competency & Written Testing Requirements 10.3 Gloved Fingertip and Thumb Sampling (GFT) Testing Cadence, Pass/Fail Thresholds & Action Plans 10.4 Media-Fill Testing Protocols: Simulation Design, Incubation Parameters & Failure Investigations 10.5 Standard Operating Procedures & Document Control 10.6 Quality Assurance & Quality Control Programs 10.7 Inspection Methods, Self-Audits & Continuous Readiness 10.8 Literature Evaluation: Research Methods, Statistics & Stability Evidence

11 Chapter 11: Regulatory Oversight, Accreditation & Drug Supply Chain

11.1 Drug Quality and Security Act (DQSA) & FDA Section 503A Traditional Pharmacies vs. Section 503B Outsourcing Facilities 11.2 State Boards of Pharmacy, FDA Guidance & Inter-Agency Regulatory Jurisdictions 11.3 Drug Supply Chain Security Act (DSCSA), Component Qualification & Certificate of Analysis (CoA) Verification 11.4 CMS, The Joint Commission, CDC, ASPEN & ASHP: Standards Beyond USP and FDA

12 Chapter 12: Safety Management, Investigations, Recalls & Waste

12.1 Root Cause Analysis (RCA), CAPA Framework & Out-of-Specification (OOS) Investigations 12.2 Adverse Drug Event Reporting, FDA MedWatch Form 3500 & Product Recall Protocols 12.3 Occupational Safety, Hazardous Waste Disposal (RCRA / EPA) & Spill Clean-up Management

7.5 Compounding Workflow: SOPs, Workflow Software, Production Queues & Labeling

Key Takeaways Explain This Topic AI

A sterile compounding workflow runs from order verification to queueing, staging, compounding with in-process checks, final verification and labeling, then dispensing. USP <797> requires SOPs for the compounding process and its support activities.

Production queues balance urgency (STAT and first doses) against batching efficiency, and every scheduled batch must fit inside its BUD and the administration time.

ISMP guidance favors compounding one CSP, or one batch, at a time in the PEC with only its own components present, verified with barcode scanning and gravimetric or image checks.

Every CSP label shows an internal ID, the active ingredients and amounts, storage conditions if not room temperature, the BUD, the dosage form, total volume if not obvious, and a single-dose or multiple-dose statement.

USP <797> also calls for labeling to show the route, special handling and warnings as applicable, the facility's contact information if the CSP leaves the facility or health system, and that the preparation is compounded.

Last updated: September 2026

7.5 Compounding Workflow: SOPs, Workflow Software, Production Queues & Labeling

A sterile compounding area is a small production line. Most errors in it, such as the wrong drug, a wrong concentration, a missed dose, an expired BUD or a mislabeled bag, come from workflow design rather than from aseptic technique. The BCSCP outline (task 1B3) names SOPs, workflow software and production queues as tools for controlling that process.

The end-to-end workflow

Loading diagram...

Each stage has its own controls:

Stage Key controls

Order verification Clinical review (dose, route, compatibility, patient factors; see 9.1); standardized concentrations and order sets

Work order and label Generated from the verified order; barcode that links to the compounding record

Staging Components pulled and checked against the work order; outer packaging removed outside the anteroom; wiped per USP <797> Section 8

Compounding MFR followed where required; scanning or independent check of each component before it is added; calculations verified

Final verification Visual inspection (particles, container integrity), label matches the order, compounding record complete, BUD correct

• Dispensing Correct storage, packaging and transport; handoff documented
• USP <797> requirements that shape workflow

SOPs (Section 17): Facilities must write SOPs for the compounding process and support activities, stating which categories of CSPs they prepare. Personnel must be trained to spot problems, deviations, failures and errors and to report them to the designated person (see 10.5).

Records (Section 11): Every Category 1, 2 and 3 CSP has a compounding record. An MFR is required for nonsterile ingredients or for more than one patient.

Release (Section 12): Visual inspection happens before release. A CSP not dispensed on the day it is made is inspected again just before it is released.

Labeling (Section 13): Labeling procedures must prevent labeling errors and CSP mix-ups.

Production queues and batch scheduling

Queues set priorities. Common tiers are STAT and first doses , then timed doses in the next delivery window, then scheduled batches such as next-day PN or cassettes. Workflow software displays each queue and flags items that are late.

Batching is efficient but has to respect three limits:

The BUD clock. A batch must be made late enough that the BUD still covers administration. For example, a Category 1 CSP made at 08:00 expires at 20:00 at room temperature, so it cannot cover a 22:00 infusion.

Stability. The labeling or literature may set a shorter limit than the USP table (see 5.2).

Sterility testing. Batches of CSPs that require sterility testing are capped at 250 units . Testing then sets both the batch sample size and the timing of release.

One preparation at a time

ISMP's guidelines for safe preparation of compounded sterile preparations advise that only the components for one CSP, or one batch, be in the PEC at a time . Separate label sets and clear staging trays per order prevent mix-ups between patients. Hazardous and non-hazardous work flows are separated physically as well as in the schedule.

Workflow software (IVWMS/DEWS)

IV workflow management systems, also called dose-edge or workflow systems, typically:

• manage queues and priorities, and show turnaround times;
• scan barcodes on every component and block wrong-product additions;
• verify volumes by weight (gravimetrics) and capture images for remote pharmacist checks;
• calculate BUDs from the product's rules;

build an electronic compounding record with lot numbers and expiration dates. USP <797> accepts electronic records from ACDs or workflow systems if they are retrievable and complete;

interface with the EHR and with PN or ACD compounding software.

The software also creates data for quality management, such as caught errors, near misses and wasted doses.

USP <797> label requirements (Section 13)

On the immediate container label (minimum):

• Assigned internal identification number (for example a barcode, prescription, order or lot number)
• Active ingredient(s) and their amounts, activities or concentrations
• Storage conditions , if other than controlled room temperature
• BUD
• Dosage form
• Total amount or volume , if not obvious from the container
• A single-dose statement, if it is a single-dose container (when space permits)
• A multiple-dose statement, if it is a multiple-dose container

In the labeling, as applicable: the route of administration, special handling instructions, warning statements, and the compounding facility's name and contact information if the CSP is sent outside the facility or health system. USP also says the labeling should indicate that the preparation is compounded .

Measuring the process

Useful workflow metrics include order-to-dispense turnaround (especially for first doses), the percentage of CSPs verified with technology, errors caught per 1,000 doses, doses wasted from expired BUDs, and batch yield. Review them with the environmental and personnel data in the quality program (see 10.6).